Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
BAYER HEALTHCARE PHARMACEUTICALS INC. v. BIOGEN IDEC MA INC.
Case Number:
2:10-cv-02734
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
September 07, 2018
Biogen Gets Win In Drug IP Fight As Judge Overrides Jury
A New Jersey federal judge on Friday overrode a jury's verdict and instead found that EMD Serono Inc. and Pfizer Inc. infringed Biogen MA Inc.'s valid patent for the multiple sclerosis treatment Avonex.
-
April 26, 2018
Serono Fights Biogen's Retrial Bid Over Nixed MS Drug Patent
A New Jersey federal jury rightly found that a Biogen MA Inc. patent covering its multiple sclerosis treatment Avonex was invalid, because while the patent covered a new process, the treatment was decades old, EMD Serono Inc. told the court Wednesday.
-
March 26, 2018
Biogen Wants Jury Verdict Overruled In MS Drug Patent Row
Biogen MA Inc. on Friday asked a New Jersey federal judge to override a jury's verdict finding claims in a patent covering the multiple sclerosis treatment Avonex invalid or to redo the trial accusing EMD Serono Inc. and Pfizer Inc. of infringing that patent.
-
February 26, 2018
Jury Sides With Pfizer, Serono In Biogen's IP Spat
After a nearly eight-year legal battle, a New Jersey federal jury Friday handed down a verdict for EMD Serono and Pfizer in a lawsuit in which Biogen asserted that the sale of Rebif, Serono's multiple sclerosis treatment co-promoted by Pfizer, infringed Biogen's patent related to its own drug Avonex.